查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1804277

POCT (就地检验) 的全球市场:产品·检验类型·适应症·技术·样品类型·购买形态·终端用户·流通管道·各地区 - 市场规模·产业动态·机会分析·预测 (2025～2033年)

Global Point-of-Care Testing Market: By product, Test Type, Indication, Technology, Sample Type, Mode of Purchase, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于对快速诊断解决方案的需求不断增长，尤其是在分散式医疗环境中，全球即时检验 (POCT) 市场正经历重大转型。预计市场规模将从 2024 年的 4,648 万美元成长至 2033 年的 8,555 万美元，预测期内的复合年增长率为 7.33%。糖尿病和心血管疾病等慢性疾病的盛行率不断上升，以及对传染病快速诊断的需求，正在推动市场扩张。

许多医疗机构正在从传统的集中式检测过渡到即时检验 (POCT)，这可以加快决策速度并提高可及性。这种转变也体现在采用率上，使用即时诊断检测 (POCT) 的医疗机构数量将从 2020 年的 42,000 家增加到 2024 年的 68,000 家。这些进步实现了即时患者数据分析，在糖尿病管理、心臟事件监测和急救等领域发挥关键作用。

市场区隔

依产品类型划分，检测试剂盒和耗材因其重复性和诊断重要性，占市场主导地位，市场占有率达 65.55%。这包括血糖试纸（128 亿美元）、侧流检测试剂盒（84 亿美元）和凝血监测试剂盒。它们在常规和紧急检测中的广泛使用持续推动着收入成长。製造技术的进步也在推动成本降低和扩大可近性。

按检测类型划分，免疫学即时诊断 (POCT) 占市场主导地位，占全球收入的 41.41% 以上。这些检测能够快速、现场诊断爱滋病毒、肝炎、心臟病和其他疾病。其易用性和成本效益（每次检测约 2.85 美元）使其成为城市和服务不足地区快速诊断的基础。

按适应症划分，传染病是主要应用领域，占超过 31.30% 的市场。呼吸道感染、爱滋病毒和肝炎的高发病率，以及公共卫生对大规模检测的需求，巩固了该领域的主导地位。 2024 年，全球进行了超过 28 亿次呼吸道检测和 14 亿次胃肠道病原体检测。

区域洞察

北美

北美是全球领先者，2024 年收入超过 186.4882 亿美元，这得益于广泛的保险覆盖和强大的医疗保健基础设施。美国是最大的市场，拥有23.8万家诊所，每年进行18亿次检测。领先研究机构和政府机构的大规模投资确保了持续的技术进步和市场渗透。

亚太地区

亚太地区是成长最快的地区，复合年增长率高达8.27%。中国、印度、日本和东南亚等国家的医疗现代化正受到政府大量资金的推动。例如，印度的 "印度医疗卫生计画" （Ayushman Bharat）服务超过5亿人，对即时诊断（POCT）的需求庞大。此外，本地製造和公私合作也进一步增强了区域能力。

欧洲

欧洲国家也正在透过欧盟招标、集中医疗保健计画以及广泛采用抗菌素抗药性检测等方式加大力度。德国、法国和英国等国家正在透过全民健康覆盖和创新拨款来增加即时诊断（POCT）的可及性。

本报告研究了全球 POCT（即时检验）市场，并提供了市场概况、影响市场成长的各种因素分析、市场规模趋势和预测、各细分市场的详细分析、竞争格局以及主要公司的概况。

目录

第1章 调查架构

  • 调查目的
  • 产品概要
  • 市场区隔

第2章 调查手法

第3章 摘要整理:全球POCT (就地检验) 市场

第4章 全球POCT (就地检验) 市场:概要

  • 价值链分析
  • 产业的展望
  • 大环境分析
  • 波特的五力分析
  • 市场动态和趋势
  • 市场成长与展望
  • 竞争仪表板
  • 实用的见解 (分析师的推荐事项)

第5章 全球POCT (就地检验) 市场分析:各产品

  • 重要的洞察
  • 市场规模·预测
    • 设备和设备
    • 检测套组与消耗品

第6章 全球POCT (就地检验) 市场分析:各检验类型

  • 重要的洞察
  • 市场规模·预测
    • 免疫学的POCT
    • 核酸为基础的POCT
    • 生物标记为基础的POCT

第7章 全球POCT (就地检验) 市场分析:各适应症

  • 重要的洞察
  • 市场规模·预测
    • 感染疾病
    • 肿瘤
    • 心血管疾病
    • 代谢障碍
    • 呼吸疾病
    • 神经疾病
    • 肠胃障碍
    • 其他

第8章 全球POCT (就地检验) 市场分析:各技术

  • 重要的洞察
  • 市场规模·预测
    • 生物感应器技术
    • 微流体实验室晶片技术
    • 分子诊断
    • 免疫检测
    • 其他

第9章 全球POCT (就地检验) 市场分析:各样品类型

  • 重要的洞察
  • 市场规模·预测
    • 血
    • 尿
    • 唾液
    • 其他

第10章 全球POCT (就地检验) 市场分析:购买不同形态

  • 重要的洞察
  • 市场规模·预测
    • 处方笺为基础检验
    • OTC检验

第11章 全球POCT (就地检验) 市场分析:各终端用户

  • 重要的洞察
  • 市场规模·预测

第12章 全球POCT (就地检验) 市场分析:各流通管道

  • 重要的洞察
  • 市场规模·预测

第13章 全球POCT (就地检验) 市场分析:各地区

  • 重要的洞察
  • 市场规模·预测
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第14章 北美的POCT (就地检验) 市场分析

  • 重要的洞察
  • 市场规模·预测
    • 各产品
    • 各检验类型
    • 各适应症
    • 各技术
    • 各样品类型
    • 各购买方法
    • 各终端用户
    • 各流通管道
    • 各国

第15章 欧洲的POCT (就地检验) 市场分析

  • 重要的洞察
  • 市场规模·预测
    • 各产品
    • 各检验类型
    • 各适应症
    • 各技术
    • 各样品类型
    • 各购买方法
    • 各终端用户
    • 各流通管道
    • 各国

第16章 亚太地区的POCT (就地检验) 市场分析

  • 重要的洞察
  • 市场规模·预测
    • 各产品
    • 各检验类型
    • 各适应症
    • 各技术
    • 各样品类型
    • 各购买方法
    • 各终端用户
    • 各流通管道
    • 各国

第17章 中东·非洲的POCT (就地检验) 市场分析

  • 重要的洞察
  • 市场规模·预测
    • 各产品
    • 各检验类型
    • 各适应症
    • 各技术
    • 各样品类型
    • 各购买方法
    • 各终端用户
    • 各流通管道
    • 各国

第18章 南美的POCT (就地检验) 市场分析

  • 重要的洞察
  • 市场规模·预测
    • 各产品
    • 各检验类型
    • 各适应症
    • 各技术
    • 各样品类型
    • 各购买方法
    • 各终端用户
    • 各流通管道
    • 各国

第19章 企业简介

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Becton, Dickinson and Company (BD)
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • 其他的主要企业

第20章 附录

简介目录
Product Code: AA07251356

The global Point-of-Care Testing (POCT) Market is undergoing a significant transformation, driven by the rising demand for rapid diagnostic solutions, especially in decentralized healthcare environments. Valued at US$ 46.48 million in 2024, the market is forecast to reach US$ 85.55 million by 2033, growing at a CAGR of 7.33% between 2025 and 2033. The accelerating prevalence of chronic illnesses such as diabetes and cardiovascular disorders, combined with the need for swift diagnosis of infectious diseases, is propelling market expansion.

A growing number of healthcare facilities are transitioning from centralized lab-based testing to POCT for faster decision-making and greater accessibility. The adoption rate reflects this shift, with 68,000 healthcare sites worldwide integrating POCT in 2024, compared to 42,000 in 2020. This evolution enables real-time patient data analysis, particularly critical in managing diabetes, monitoring cardiac events, and administering treatment during emergencies.

Noteworthy Market Developments

The year 2024 saw 67 new POCT devices cleared by the FDA, a testament to the market's innovation momentum. Several of these solutions are equipped with AI capabilities and integrated with Electronic Health Records (EHRs) to streamline clinical workflows. Multiplex assays capable of detecting multiple pathogens from a single sample are also revolutionizing diagnostics by reducing testing complexity and result turnaround time.

Concurrently, the at-home testing segment is expanding rapidly, supported by regulatory endorsements such as the FDA's clearance of an over-the-counter dual test for influenza and COVID-19 in early 2025. Companies are investing in developing portable PCR-based systems and mobile diagnostics suited for emergency and rural environments. The direct-to-consumer market alone is expected to grow from US$ 7.8 billion in 2025 to over US$ 11.8 billion by 2035.

Strategic partnerships, acquisitions, and technology funding have shaped a competitive environment where companies such as Roche, Abbott, and Danaher are not only consolidating their market position but also pioneering advanced diagnostics through AI, cloud connectivity, and miniaturized devices.

Core Growth Drivers

  • Chronic Disease Burden: Increasing global incidence of diabetes, cardiovascular disorders, and infectious diseases demanding continual monitoring.
  • Rapid Diagnostics Demand: Emergency and remote settings necessitate quicker turnaround times, fueling POCT adoption.
  • Technological Integration: AI, cloud computing, and smartphone compatibility are enhancing test accuracy and accessibility.
  • Regulatory Acceleration: Government incentives and expedited device approvals are encouraging market entry and innovation.
  • Decentralized Healthcare Models: Shifting care delivery to homes, pharmacies, and community health centers is creating sustained demand.

Emerging Technology Trends

  • AI in Diagnostics: Integration of machine learning to interpret results and guide clinical decisions is becoming a standard feature in new POCT devices.
  • Multiplex POCT Assays: Advanced tests that detect multiple biomarkers in one go are growing at a projected rate of 25%.
  • Smartphone Connectivity: The number of devices linked to smartphones is set to increase by 30%, facilitating remote care models.
  • Cloud-Based Reporting: The use of cloud platforms for real-time result sharing and storage is expected to grow by 35% over the next few years.
  • Miniaturized Platforms: Portable diagnostics, such as mobile CT and PCR devices, are making POCT viable even in ambulances and rural settings.

Barriers to Optimization

  • High Cost of Advanced Devices: AI-integrated and multiplex systems come with significant capital and operational expenses.
  • Training and Standardization Gaps: Ensuring accuracy in non-laboratory environments remains a challenge due to variability in user expertise.
  • Regulatory Complexity Across Regions: Diverse regulations for OTC vs. prescription-based testing can complicate global product rollouts.
  • Data Security: The rise in cloud-based diagnostics raises cybersecurity concerns related to patient data.

Market Segment Analysis

The Testing Kits & Consumables category leads the market with a 65.55% share, driven by their recurring nature and indispensable use in diagnostics. These include high-demand items like glucose test strips (US$ 12.8 billion), lateral flow cartridges (US$ 8.4 billion), and coagulation monitoring kits. Their role in routine and emergency testing ensures a continuous revenue stream, with advanced manufacturing helping reduce costs and widen accessibility.

From a test-type perspective, Immunological PoC Tests dominate the landscape, contributing over 41.41% of global revenue. These tests enable fast, point-of-use diagnosis of conditions like HIV, hepatitis, and cardiac diseases. Their ease of use and cost-effectiveness (as low as US$ 2.85/test) have made them the cornerstone of rapid diagnostics in both urban and underserved settings.

In terms of indication, Infectious Diseases remain the primary application, accounting for over 31.30% of the market. High incidence rates of conditions like respiratory infections, HIV, and hepatitis, combined with public health mandates for mass testing, reinforce this segment's leadership. More than 2.8 billion respiratory tests and 1.4 billion gastrointestinal pathogen tests were conducted globally in 2024.

Additionally, Prescription-Based Testing remains the dominant mode, holding a 53.25% share. These tests, such as HbA1c and metabolic panels, require physician oversight and are tightly integrated into insurance reimbursement and regulatory frameworks, ensuring quality and proper clinical guidance.

Market Segmentation

By Product

  • Devices & Instruments
  • Diagnostic Analyzers & Testing Devices
  • Blood Gas & Electrolyte Analyzers
  • Cardiac Biomarker Analyzers
  • Glucose Monitoring Devices
  • Coagulation Testing Analyzers
  • Urinalysis Analyzers
  • Routine Clinical Chemistry Analyzers
  • Others
  • Monitoring Devices
  • Blood Pressure Monitors
  • Thermometers
  • Pulse Oximeters
  • Others
  • Testing Kits & Consumables
  • Blood Gas & Electrolyte Test Kits
  • Cardiac Biomarker Test Kits
  • Routine Clinical Chemistry Test Kits
  • Hematology Test Kits Coagulation Testing Kits
  • Urinalysis Test Strips & Kits
  • Cholesterol Test Strips
  • Drugs Abuse Testing Kits
  • Pregnancy And Fertility Testing Kits
  • Others

By Test Type

  • Immunological PoC Tests
  • Nucleic Acid-Based PoC Tests
  • Biomarker-Based PoC Tests

By Indication

  • Infectious Diseases
  • HIV
  • COVID-19
  • Others
  • Oncology
  • Cardiovascular Diseases
  • Metabolic Disorders
  • Respiratory Diseases
  • Neurological Disorders
  • Gastrointestinal Disorders
  • Others

By Technology

  • Biosensor Technology
  • Microfluidic Lab-On-A-Chip Technology
  • Molecular Diagnostics
  • Immunoassays
  • Others

By Sample Type

  • Blood
  • Urine
  • Saliva
  • Others

By Mode Of Purchase

  • Prescription-based Testing
  • Over the Counter (OTC) Testing

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Homecare Settings
  • Research Laboratories
  • Others

By Distribution Channel

  • Direct Distribution
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Geographic Insights

North America

North America stands as the global leader, with 2024 revenue exceeding US$ 18,648.82 million, supported by extensive insurance coverage and robust healthcare infrastructure. The U.S., in particular, is the top-performing country, conducting 1.8 billion annual tests across 238,000 physician offices. Massive investment from leading institutions and government bodies ensures continued technological advancement and market penetration.

Asia Pacific

Asia Pacific is the fastest-growing region with a CAGR of 8.27%. Healthcare modernization across countries such as China, India, Japan, and Southeast Asia is bolstered by massive government funding. For instance, India's Ayushman Bharat scheme serves over 500 million citizens, driving high-volume POCT demand. Local manufacturing and public-private partnerships further amplify regional capabilities.

Europe

European nations are also ramping up efforts through EU tenders, centralized healthcare initiatives, and widespread adoption of antimicrobial resistance testing. Countries like Germany, France, and the UK are enhancing POCT accessibility through universal health schemes and innovation grants.

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Hungary
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • UAE
  • Saudi Arabia
  • Bahrain
  • Kuwait
  • Qatar
  • Rest of Middle East
  • Africa
  • Morocco
  • Egypt
  • Nigeria
  • South Africa
  • Rest of Africa
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Leading Market Participants

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Becton, Dickinson and Company (BD)
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Type Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Point-of-Care Testing Market

Chapter 4. Global Point-of-Care Testing Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunities
    • 4.5.4. Key Trends
  • 4.6. Market Growth and Outlook
    • 4.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
    • 4.6.2. Price Trend Analysis
  • 4.7. Competition Dashboard
    • 4.7.1. Market Concentration Rate
    • 4.7.2. Company Market Share Analysis (Value %), 2024
    • 4.7.3. Competitor Mapping & Benchmarking
  • 4.8. Actionable Insights (Analyst's Recommendations)

Chapter 5. Global Point-of-Care Testing Market Analysis, By Product

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 5.2.1. Devices & Instruments
      • 5.2.1.1. Diagnostic Analyzers & Testing Devices
        • 5.2.1.1.1. Blood Gas & Electrolyte Analyzers
        • 5.2.1.1.2. Cardiac Biomarker Analyzers
        • 5.2.1.1.3. Glucose Monitoring Devices
        • 5.2.1.1.4. Coagulation Testing Analyzers
        • 5.2.1.1.5. Urinalysis Analyzers
        • 5.2.1.1.6. Routine Clinical Chemistry Analyzers
        • 5.2.1.1.7. Others
      • 5.2.1.2. Monitoring Devices
        • 5.2.1.2.1. Blood Pressure Monitors
        • 5.2.1.2.2. Thermometers
        • 5.2.1.2.3. Pulse Oximeters
        • 5.2.1.2.4. Others
    • 5.2.2. Testing Kits & Consumables
      • 5.2.2.1. Blood Gas & Electrolyte Test Kits
      • 5.2.2.2. Cardiac Biomarker Test Kits
      • 5.2.2.3. Routine Clinical Chemistry Test Kits
      • 5.2.2.4. Hematology Test Kits Coagulation Testing Kits
      • 5.2.2.5. Urinalysis Test Strips & Kits
      • 5.2.2.6. Cholesterol Test Strips
      • 5.2.2.7. Drugs Abuse Testing Kits
      • 5.2.2.8. Pregnancy And Fertility Testing Kits
      • 5.2.2.9. Others

Chapter 6. Global Point-of-Care Testing Market Analysis, By Test Type

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 6.2.1. Immunological PoC Tests
    • 6.2.2. Nucleic Acid-Based PoC Tests
    • 6.2.3. Biomarker-Based PoC Tests

Chapter 7. Global Point-of-Care Testing Market Analysis, By Indication

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 7.2.1. Infectious Diseases
      • 7.2.1.1. HIV
      • 7.2.1.2. COVID-19
      • 7.2.1.3. Others
    • 7.2.2. Oncology
    • 7.2.3. Cardiovascular Diseases
    • 7.2.4. Metabolic Disorders
    • 7.2.5. Respiratory Diseases
    • 7.2.6. Neurological Disorders
    • 7.2.7. Gastrointestinal Disorders
    • 7.2.8. Others

Chapter 8. Global Point-of-Care Testing Market Analysis, By Technology

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 8.2.1. Biosensor Technology
    • 8.2.2. Microfluidic Lab-On-A-Chip Technology
    • 8.2.3. Molecular Diagnostics
    • 8.2.4. Immunoassays
    • 8.2.5. Others

Chapter 9. Global Point-of-Care Testing Market Analysis, By Sample Type

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 9.2.1. Blood
    • 9.2.2. Urine
    • 9.2.3. Saliva
    • 9.2.4. Others

Chapter 10. Global Point-of-Care Testing Market Analysis, By Mode of Purchase

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 10.2.1. Prescription-based Testing
    • 10.2.2. Over the Counter (OTC) Testing

Chapter 11. Global Point-of-Care Testing Market Analysis, By End User

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2033 (US$ Mn)
      • 11.2.1.1. Hospitals & Clinics
      • 11.2.1.2. Diagnostic Centers
      • 11.2.1.3. Homecare Settings
      • 11.2.1.4. Research Laboratories
      • 11.2.1.5. Others

Chapter 12. Global Point-of-Care Testing Market Analysis, By Distribution Channel

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2033 (US$ Mn)
      • 12.2.1.1. Direct Distribution
      • 12.2.1.2. Retail Pharmacies
      • 12.2.1.3. Online Pharmacies
      • 12.2.1.4. Others

Chapter 13. Global Point-of-Care Testing Market Analysis, By Region

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 13.2.1. North America
      • 13.2.1.1. The U.S.
      • 13.2.1.2. Canada
      • 13.2.1.3. Mexico
    • 13.2.2. Europe
      • 13.2.2.1. Western Europe
        • 13.2.2.1.1. The UK
        • 13.2.2.1.2. Germany
        • 13.2.2.1.3. France
        • 13.2.2.1.4. Italy
        • 13.2.2.1.5. Spain
        • 13.2.2.1.6. Rest of Western Europe
      • 13.2.2.2. Eastern Europe
        • 13.2.2.2.1. Poland
        • 13.2.2.2.2. Russia
        • 13.2.2.2.3. Rest of Eastern Europe
    • 13.2.3. Asia Pacific
      • 13.2.3.1. China
      • 13.2.3.2. India
      • 13.2.3.3. Japan
      • 13.2.3.4. South Korea
      • 13.2.3.5. Australia & New Zealand
      • 13.2.3.6. ASEAN
      • 13.2.3.7. Rest of Asia Pacific
    • 13.2.4. Middle East & Africa
      • 13.2.4.1. UAE
      • 13.2.4.2. Saudi Arabia
      • 13.2.4.3. South Africa
      • 13.2.4.4. Rest of MEA
    • 13.2.5. South America
      • 13.2.5.1. Argentina
      • 13.2.5.2. Brazil
      • 13.2.5.3. Rest of South America

Chapter 14. North America Point-of-Care Testing Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 14.2.1. By Product
    • 14.2.2. By Test Type
    • 14.2.3. By Indication
    • 14.2.4. By Technology
    • 14.2.5. By Sample Type
    • 14.2.6. By Mode of Purchase
    • 14.2.7. By End User
    • 14.2.8. By Distribution Channel
    • 14.2.9. By Country

Chapter 15. Europe Point-of-Care Testing Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 15.2.1. By Product
    • 15.2.2. By Test Type
    • 15.2.3. By Indication
    • 15.2.4. By Technology
    • 15.2.5. By Sample Type
    • 15.2.6. By Mode of Purchase
    • 15.2.7. By End User
    • 15.2.8. By Distribution Channel
    • 15.2.9. By Country

Chapter 16. Asia Pacific Point-of-Care Testing Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 16.2.1. By Product
    • 16.2.2. By Test Type
    • 16.2.3. By Indication
    • 16.2.4. By Technology
    • 16.2.5. By Sample Type
    • 16.2.6. By Mode of Purchase
    • 16.2.7. By End User
    • 16.2.8. By Distribution Channel
    • 16.2.9. By Country

Chapter 17. Middle East & Africa Point-of-Care Testing Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 17.2.1. By Product
    • 17.2.2. By Test Type
    • 17.2.3. By Indication
    • 17.2.4. By Technology
    • 17.2.5. By Sample Type
    • 17.2.6. By Mode of Purchase
    • 17.2.7. By End User
    • 17.2.8. By Distribution Channel
    • 17.2.9. By Country

Chapter 18. South America Point-of-Care Testing Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 18.2.1. By Product
    • 18.2.2. By Test Type
    • 18.2.3. By Indication
    • 18.2.4. By Technology
    • 18.2.5. By Sample Type
    • 18.2.6. By Mode of Purchase
    • 18.2.7. By End User
    • 18.2.8. By Distribution Channel
    • 18.2.9. By Country

Chapter 19. Company Profile (Company Overview, Financial Matrix, Key Type landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 19.1. Abbott Laboratories
  • 19.2. F. Hoffmann-La Roche Ltd
  • 19.3. Danaher Corporation
  • 19.4. Becton, Dickinson and Company (BD)
  • 19.5. bioMerieux SA
  • 19.6. Bio-Rad Laboratories, Inc.
  • 19.7. Other Prominent Players

Chapter 20. Annexure

  • 20.1. List of Secondary Sources
  • 20.2. Key Country Markets - Marco Economic Outlook/Indicators